




A Novel Synthesis of 9,13-dicis Double Bonds Locked Retinoids

Feng-Ling Qing* and Xiang-Jun Yue

Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
354 FengLin Lu, Shanghai 200032, P.R. China

Abstract: Synthesis of two retinoids in which the 9,13-dicis double bonds were locked in cycloalkene or thiophene was described. The key step was carbonylation of vinyl bromide **9** and **16** with carbon monoxide in the presence of $\text{Pd}(\text{PPh}_3)_4$. © 1997 Elsevier Science Ltd.


Retinoids are natural and synthetic analogs of Vitamin A. Because of their far ranging biological effects, retinoids have found clinical applications in dermatology, oncology and show promise in other diverse therapeutic areas including arthritis, dyslipidemias, and the prevention of HIV-induced lymphopenia. Cumulative evidence has indicated that retinoids may exert their functions by regulating gene expression mediated by two classes of nuclear receptors: the retinoic acid receptor family (RAR)¹ and the retinoid X receptor family (RXR)². The physiological hormones for the RAR and RXR are proposed to be all-*trans*-retinoic acid (RA) and 9-*cis*-retinoic acid (9-*cis* RA) respectively. However, 9-*cis* RA can bind to and transcriptionally activates the RAR as well³. Unfortunately, use of the retinoids is associated with a number of significant side effects and therefore widespread clinical use of retinoids is severely limited. In view of the related, but clearly distinct, nature of these receptors, ligands which are selective for the RAR or RXR family would provide the capacity for independent control of the physiologic processes mediated by the RAR or RXR and further offer the possibility of improved therapeutic indices and reduced toxicity⁴. Recently, identification of 9,13-dicis-retinoic acid as a major plasma metabolite of 9-*cis*-RA has been reported⁵. In order to investigate the function of 9,13-dicis RA and obtain the selective substances for RXR or RAR receptor, we were interested in designing and preparing compounds **1** and **2** in which the 9-*cis* and 13-*cis* double bond are locked in cyclohexene or thiophene and cyclopentene respectively.





Bromide **3** (Scheme 1), prepared in 85% yield by reaction of *o*-bromotoluene with 2,5-dichloro-2,5-dimethylhexane in the presence of aluminum chloride, was used as the starting material for the synthesis of **1**. Bromide **3** was treated with *tert*-butyl lithium at -78°C , followed by zinc chloride at room temperature to give the organozinc compound, which is in turn reacted with ethyl 2-trifluoromethanesulfonyloxycyclohexene-1-ylcarboxylate **4**⁶ under palladium(0) catalysis⁷ to give ester **5** in 85% yield. This is the first example of palladium-catalyzed cross-coupling of 2-carboethoxy enol triflate with an aryl zinc compound. Lithium aluminium hydride reduction of the ester **5** to the alcohol **6**, followed by reaction with triphenylphosphine hydrogen bromide in dried methanol afforded the phosphonium salt **7** quantitatively. Wittig olefination of phosphonium salt **7** with 2-bromocyclopentene-1-ylaldehyde **8**⁸ in dried dichloromethane in the presence of potassium *tert*-butoxide gave the single *trans* isomer vinyl bromide **9** in 94% yield. The *trans* isomer was determined by the coupling constant of two vinyl protons ($J_{\text{H,H}} = 16.0$ Hz). Carbonylation of the unstable vinyl bromide **9** with carbon monoxide in DMF under palladium(0) catalysis⁹ at 85°C afforded methyl carboxylate **10** in 76% yield. The ester **10** was cleanly saponified to the 9,13-dicis-blocked acid **1**¹⁰.


Scheme 1.



Reagents and Conditions: a) *t*-BuLi, -78°C , then ZnCl_2 room temperature, then $\text{Pd}(\text{PPh}_3)_4$ and **4**; b) LiAlH_4 ; c) $\text{Ph}_3\text{P.HBr}$, MeOH; d) *t*-BuOK, CH_2Cl_2 then **8**; e) CO, $\text{Pd}(\text{PPh}_3)_4$, MeOH, Et_3N , DMF, 85°C ; f) aq. KOH, MeOH, reflux, then HCl

We then turned our attention to the synthesis of **2** (Scheme 2). Our initial approach to the key intermediate **13** by the cross-coupling of the corresponding organozinc compound of aryl bromide **3** with methyl 3-bromo-2-thiophenecarboxylate **12**¹¹ under palladium (0) or nickel(0) catalysis¹² failed and the compound **12** was recovered. Therefore, an alternative route was adopted for preparation of **13**. Aryl bromide **3** was reacted with *t*-butyllithium, followed by the addition of triisopropylborate and then hydrolysis to a boronic acid **11** in 75% yield. The Suzuki cross-coupling¹³ of boronic acid **11** with **12** in the presence of Pd(PPh₃)₄ gave the ester **13** in 98% yield. Then the methodology used in Scheme 1 was extended to the preparation of **2**. Thus, in an analogous manner, phosphonium salt **15** was prepared from **13**. However, Wittig-olefination of phosphonium salt **15** with **8** afforded the mixture of vinyl bromide **16** in a ratio of *trans*:*cis* of 8:5 (as determined by ¹H NMR). The mixed vinyl bromide **16** could not be separated by column chromatography and used directly in carbonylation. The mixed ester **17** was hydrolyzed to give a solid which after recrystallization from absolute ethyl alcohol to afford the desired acid **2**¹⁴.

Scheme 2.



Reagents and Conditions: a) *t*-BuLi, -78°C, then B(OPr-i)₃, R.T., HCl
 b) Pd(PPh₃)₄, NaHCO₃, DME, R.T.; c) LiAlH₄; d) Ph₃P.HBr, MeOH;
 e) *t*-BuOK, CH₂Cl₂; f) CO, Pd(PPh₃)₄, MeOH, Et₃N, DMF, 85°C;
 g) aq.KOH, MeOH, reflux, then HCl, Recrystallized from ethyl alcohol

The successful approach described herein, enabled us to synthesize a number of analogues related to **1** and **2**. The structure-activity relationships of these derivatives and their ability to transactivate RAR or RXR selectively will be reported in a future publication.

References and Notes

1. (a) Petkovich, M.; Brand, N.J.; Kurst, A.; Chambon, P. *Nature* **1987**, 330, 444. (b) Giguere, V.; Ong, E.S.; SEgui, P.; Evans, R.M. *Nature* **1987**, 330, 624. (c) Benbrook, D.; Lerhardt, E.; Pfahl, M. *Nature* **1988**, 333, 669.
2. (a) Hamada, K.; Gleason, S. L.; Levi, B. Z.; Hirschfeld, S.; Appella, E.; Ozato, K. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, 86, 8289. (b) Mangelsdorf, D.J.; Ong, E.S.; Dyck, J.A.; Evans, R.M. *Nature* **1990**, 345, 224. (c) Leid, M.; Kastner, P.; Lyons, R.; Nakshari, H.; Saunders, M.; Zacharewski, T.; Chen, J.Y.; Staub, A.; Garnier, J.M.; Mader, S.; Chambon, P. *Cell* **1992**, 68, 377.
3. (a) Heyman, R.A.; Mangelsdorf, D.J.; Dyck, J.A.; Stein, R. B.; Eichel, G.; Evans, R.M.; Thaller, C. *Cell* **1992**, 68, 397. (b) Allenby, G.; Bocquel, M. T.; Sauders, M.; Kazmer, S.; Speck, T.; Rosenberger, M.; Lovey, A.; Kastner, P.; Grippo, J. F.; Chambon, P.; Levin, A. A. *Proc. Natl. Acad. Sci. U.S.A.* **1993**, 90, 30. (c) Levin, A. A.; Sturzenbecker, L. J.; Kazmer, S.; Bosenberger, M.; Lovey, A.; Grippo, J. F. *Nature* **1992**, 355, 359.
4. (a) Nadzan, A. M. *Annual Reports in Medical Chemistry*, 1995, Academic Press, Inc.; P. 119. (b) Dawson, M. I.; Jong, L.; Hobbs, P. D.; Cameron, J. F.; Chao, W. R.; Ptahl, M.; Lee, M. O.; Shroot, B.; Pfahl, M. *J. Med. Chem.* **1995**, 38, 3368.
5. Tzimas, G.; Sass, J. O.; Wittfoht, W.; Elmazar, M. M. A.; Ehlers, K.; Nau, H. *Drug Metab. Dispos.* **1994**, 22, 928.
6. Crisp, G. T.; Meyer, A. G. *J. Org. Chem.* **1992**, 57, 6972.
7. Arcadi, A.; Byrini, A.; Cacchi, S.; Delmastro, M.; Marinelli, F.; Pietroni, B. *Synlett*. **1990**, 47.
8. Arnold, Z.; Holy, A. *Collect. Czech. Chem. Commun.* **1961**, 26, 3059.
9. Cacchi, S.; Morera, E.; Ortari, G. *Tetrahedron Lett.* **1985**, 26, 1109.
10. Compound 1: m.p. 264-264.5°C; ¹H NMR(300 MHz, CDCl₃): δ: 1.22(s, 3H), 1.25(s, 3H), 1.26(s, 3H), 1.28(s, 3H), 1.72(s, 4H), 1.73-1.79(m, 6H), 2.08(s, 3H), 2.33-2.40(m, 6H), 2.67(t, J=7.0Hz, 2H), 6.27(d, J=16.0Hz, 1H), 6.89(s, 1H), 7.08(s, 1H), 7.37(d, J=16.0Hz, 1H)ppm; ¹³C NMR(75 MHz, CDCl₃): δ: 19.18, 21.38, 22.78, 23.02, 25.11, 31.89, 32.09, 32.27, 33.20, 34.16, 35.37, 120.61, 126.70, 126.84, 127.68, 131.31, 132.13, 137.35, 139.49, 141.98, 143.27, 144.26, 156.24, 171.34 ppm; IR(KBr): γ_{max}: 3069, 3015, 2925, 2589, 1666, 1655, 1568, 1495, 1446, 1391, 1361, 1282, 1263, 1247, 978, 894, 766 cm⁻¹. UV(in CH₂Cl₂): 330 nm; MS(EI): 418(M⁺, 60), 385(84), 281(100), 195(55), 123(61), 111(75), 69(47), 57(49); HRMS: calcd for C₂₉H₃₅O₂ 418.2853, found 418.2834.
11. Tserng, K. Y.; Bauer, L. *J. Org. Chem.* **1975**, 40, 172.
12. Negishi, E. I. *Acc. Chem. Res.* **1982**, 15, 340.
13. Miyaura, N.; Yanagi, T.; Suzuki, A. *Synth. Commun.* **1981**, 11, 513.
14. Compound 2: m. p. 238-239°C; ¹H NMR(300 MHz, CDCl₃): δ: 1.27(s, 6H), 1.32(s, 6H), 1.70(s, 4H), 1.85(pent, J=7.0Hz, 2H), 2.17(s, 3H), 2.62(t, J=7.0Hz, 2H), 2.75(t, J=7.0Hz, 2H), 6.73(d, J=16.0Hz, 1H), 7.00(d, J=5.0Hz, 1H), 7.08(s, 1H), 7.19(s, 1H), 7.27(d, J=5.0Hz, 1H), 7.87(d, J=16.0Hz, 1H)ppm; ¹³C NMR(75Hz, CDCl₃): δ: 20.13, 21.48, 31.93, 32.03, 34.14, 34.25, 34.49, 35.35, 123.35, 124.47, 128.30, 128.41, 128.96, 129.21, 130.73, 132.73, 133.43, 138.17, 142.25, 142.85, 144.49, 154.45, 170.20 ppm; IR(KBr): γ_{max}: 3053, 2927, 2615, 1719, 1668, 1600, 1492, 1391, 1272, 1094, 908, 733, 689, cm⁻¹. UV(in CH₂Cl₂): 340nm; MS(EI): 420(M⁺, 100), 405(21), 387(45), 279(70), 3239(27). HRMS: calcd for C₂₇H₃₂ O₂S 420.2097, found 420.2071.

(Received in China 18 August 1997; accepted 4 September 1997)